When GlaxoSmithKline ($GSK) bought out GlycoVaxyn for $190 million earlier this year, it gained a set of early-stage vaccines and commissioned GlycoVaxyn's team to create a new company around its existing research operation. That company is LimmaTech Biologics, and now, it and GSK have struck a 5-year exclusive agreement to develop novel bioconjugate antigen-based vaccines. Though Glaxo retains full ownership of any vaccines developed by GlycoVaxyn--as well as any new candidates LimmaTech may come up with--the biotech can also develop therapeutics outside of vaccines. More from FierceVaccines